. Analysis of transcript levels from different regions of the Tfap2a locus. qRT-PCR was performed on RNA isolated from E10.5 faces of the mouse genotypes indicated. A) Ratios of Tfap2a exon 2-3 levels relative to Gapdh and B) exon 6-7 levels relative to Gapdh. The ratio for the wild-type (WT) Tfap2a levels relative to Gapdh is arbitrarily set to 1. Bracket denotes samples that were not statistically different from each other, but were different from all other groups and "*" denotes P-value <0.05 from all other groups. Tfap2a gene organization and position of qRT-PCR assays is shown in Figure 1A . There was an ~2 fold reduction in transcripts derived from upstream exons in the various Tfap2a mutant genotypes compared to wild-type, and a significantly greater reduction in normal transcripts containing downstream exons, especially in the Neo/ Null embryos. C) Model of the alternate splicing products derived from the Neo allele based on sequence analysis of products shown in Figure 1K . The allele can produce a wild-type transcript (top), or any of the transcript variants detected (Var1-Var 3). The splice products identified by sequencing the variant PCR products are shown on the left, and their predicted protein products are shown on the right. The blue regions in the protein product show the basic region and the helix-span-helix domains that are part of the DNA binding and dimerization domain. In all instances, the proteins produced from the aberrantly spliced products would lack a functional DNA binding and dimerization domain. D) The amino acid (AA) sequence of the wild-type protein spanning exons 5-7 is shown at the top, and the altered sequences predicted from the aberrantly spliced transcripts are shown below. An asterisk indicates a stop codon, and AA sequence shown in color illustrates protein sequence at the C-terminus unrelated to AP-2a sequence that results from aberrant splicing.
Phosphatase inhibitor treated lysates from E10.5 dissected faces were probed for phospho-Erk and total Erk1 and Erk2. Microarray data analysis coupled with Western blotting indicated that there are no significant changes in Mapk1 or Erk levels between Neo/Wt or Neo/Null mice. With respect to phospho-Erk, we could not detect these modified protein isoforms above background using this assay in either mouse sample and so it was not possible to determine if this showed a significant change in the Neo/Null sample from the Neo/Wt.
Movie S1: Mathematical timelapse of facial development in Neo/Wt embryos. Movie shows timelapse between E10.5-E11.5 for Neo/Wt end of PC4 (E10.5) to the Neo/Wt end of PC1 (E11.5).
Movie S2: Mathematical timelapse of facial development in Neo/Null embryos. Movie shows timelapse between E10.5-E11.5 for Neo/Null end of PC4 (E10.5) to the Neo/Null end of PC1 (E11.5).
Supplemental Table 1:
List of landmarks for E9.5 embryos. Numbers in parentheses represent the right side of the embryo. Table 2: P-values from permutation tests (10000 permutation rounds) for Procrustes distances between groups from CVA tests (Figure 2A ). Note that all "between group differences" reach statistical significance at a P value of <0.05. Results of microarray analysis of gene expression in E10.5 nasal prominences performed in triplicate on independent sample pools. Attached spreadsheet shows list of genes in the nasal process with a present call in both Neo/Null (nnb) and Neo/Wt (wnb) groups, showing a >1.25 fold difference, and a P-value of <0.05.
Download Table S3
Supplemental Table 4 :
Results of microarray analysis of gene expression in E10.5 maxillary prominence performed in triplicate on independent sample pools. Attached spreadsheet shows list of genes in the maxilla with a present call in both Neo/Null (nxb) and Neo/Wt (wxb) groups, showing a >1.25 fold difference, and a P-value of <0.05.
Download Table S4
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